Substance-Related Disorders
66 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Acceptance and Commitment Therapy + Ketamine for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Baclofen for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Baclofen for liver diseases, alcoholic | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brenipatide for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Brenipatide for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brief Negotiation Interview for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brief Negotiation Interview + Naltrexone + Gabapentin for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cabotegravir for substance-related disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cannabidiol for marijuana abuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Cannabidiol + Dronabinol for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet + Naproxen 500 Mg + Opioids for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CI-581a for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Combined LAI Treatment: Cabenuva and Sublocade for opioid-related disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Contingency management for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Counseling + Quitting using Medication for substance-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Counseling + Switching to E-Cigarette for substance-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Daridorexant for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DBS of the NAc for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Simulator for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diamorphine hydrochloride anhydrous for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dronabinol for marijuana abuse | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DynamiCare Health for opioid-related disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| E-Cigarette 7.2 mg nicotine for tobacco use disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| electronic cigarette for tobacco use disorder | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Endd (njoy) for tobacco use disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Faecal microbiota transplantation for hepatitis, alcoholic | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High THC Cannabis for marijuana abuse | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ibogaine hydrochloride for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Increasing control over stimulant use and physical health through incentivized rehabilitation for substance-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine for cocaine-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine Hydrochloride for alcoholism | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| kudzu extract, puerarin for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lifus for substance-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-intensity focused ultrasound for cocaine-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-intensity focused ultrasound for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Low-Intensity Focused Ultrasound + Low-Intensity Focused Ultrasound - sham for opioid-related disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matched Placebo (oral gummy) + Δ9-Tetrahydrocannabivarin (oral gummy) for tobacco use disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Intramuscular Placebo + IBOGAINE HYDROCHLORIDE for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MDMA Assisted Therapy for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Midomafetamine for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Midomafetamine for substance-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mindset for alcohol-related disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Next Generation Dome Helmet (NGDH) for substance-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Pemvidutide for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Nimodipine for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prolonged exposure therapy + MIDOMAFETAMINE for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 8 |
| Psilocybin for cocaine-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psychotherapy for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psychotherapy + Medication for opioid use disorder for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Questionnaires for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| real-time fMRI neurofeedback training for cocaine-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| real-time fMRI neurofeedback training + Ketamine for cocaine-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recovery Management Checkups (RMC) delivered by community-based agencies (RMC adopters) for alcoholism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recovery Management Checkups (RMC) delivered by community-based agencies (RMC adopters) for opioid-related disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semaglutide for alcoholism | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| STAM 1100mAh CE4 eGo Clearomizer for tobacco use disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Standardized kudzu for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tirzepatide for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Treatment with Ketone Supplement for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Treatment with Placebo for opioid-related disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Varenicline for marijuana use | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Varenicline for tobacco use disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zonisamide for alcoholism | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |